Who Is Responsible for Biotech's Torrid Start to 2014?

Biotech investing goes mainstream.

Feb 20, 2014 4:03 PM EST

A tweet and a chart to think about.

Was traveling in midwest y'day to see ISI clients. Huge generalist interest in biotech & pharma right now. I mean off the charts.
Mark Schoenebaum (@MarkSchoenebaum) February 20, 2014

IBB data by YCharts

I'd say there's a link between the two.

If you liked this article you might like

Nothing's happening, but that doesn't mean you have to make something happen.

Jim Cramer

Aug 21, 2017 12:05 PM EDT

The market seems fully valued, so I'm building up cash as we head into historically volatile months.

Bret Jensen

Aug 14, 2017 2:30 PM EDT

Stop losses do not work in this part of the market.

Bret Jensen

Aug 13, 2017 10:00 AM EDT

Stop losses do not work in this part of the market.

Bret Jensen

Aug 11, 2017 11:30 AM EDT

CELG looks like it has a promising future, according to the charts.

Bruce Kamich

Aug 3, 2017 9:25 AM EDT

Who Is Responsible for Biotech's Torrid Start to 2014?

Biotech investing goes mainstream.

If you liked this article you might like

Trending

Advertising Partners

If you liked this article you might like

Cramer: Random Movement Is Exactly That

Be Cautious in Case of a Second-Half Hiccup

Back to Basics in Biotech

Back to Basics in Biotech

Looking to Buy Some Celgene? Now's a Good Time

Trending